Dr. Wagner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-5204Fax+1 617-632-3408
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2005- Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1997
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 1999 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors Start of enrollment: 2007 Aug 01
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Start of enrollment: 2010 Sep 01
- Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia Start of enrollment: 2014 Dec 01
Publications & Presentations
PubMed
- A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik
Clinical Cancer Research. 2025-02-17 - Impact of a Worklist Reprioritization Initiative to Improve Report Availability for Same-Day Imaging and Clinic Visits.Caroline Peers, Ronilda Lacson, M Stephen Ledbetter, Andrew J Wagner, Catherine S Giess
Journal of the American College of Radiology. 2025-01-30 - 1 citationsA phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously tre...Jayesh Desai, Andrew J Wagner, Irene Carrasco Garcia, Marilena Cesari, Michael Gordon
Cancer. 2025-01-01
Lectures
- ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open l...2019 ASCO Annual Meeting - 6/1/2019
- Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su)...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
A Rare Occurrence of BHD and PEComa – Perspectives from a Patient and a DoctorMarch 18th, 2022
Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComaNovember 14th, 2019
Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComaJune 4th, 2019- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
